SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents of $238.9M in Q1 FY2026
Q1 FY2026 cash & equivalents was $238.9M.
Context
- Cash & equivalents amounted to 92.5% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 96.36M USD
- Year-over-year change
- —
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.36M | — |
Cash & Equivalents vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Cash & equivalents amounts to 92.5% of total assets for SGP, versus a peer median of 26.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.71B USD | +13.9% | +15.9% | 5.4% | |
| Mar 2026 | $666.7M USD | +90.7% | +93.1% | 91.0% | |
| Jun 2026 | $367M USD | +34.9% | +0.3% | 2.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $238.9M USD | — | — | 92.5% |
| Apr 2026 | $131.86M USD | -23.8% | +21.0% | 29.2% | |
| Jun 2026 | $114.49M USD | +13.6% | -8.8% | 12.4% | |
| Mar 2026 | $84.96M USD | -21.9% | -20.8% | 77.4% | |
| Mar 2026 | $77.71M USD | -8.7% | +2.1% | 27.0% | |
| Mar 2026 | CHF 64.37M CHF | +7.5% | +60.2% | 26.5% | |
| Mar 2026 | $17.57M USD | -37.2% | +19.0% | 5.8% | |
| Peer median (excluding SGP) | — | +7.5% | +15.9% | 26.5% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.